Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.

OBJECTIVE

Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers.

METHODS

Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/1 (n=5), CYP3A51/3 (n=7), or CYP3A53/*3 (n=7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype.

RESULTS

The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/3 (830.5+/-160.4 ng . h/mL [mean+/-SD]) than in those with CYP3A51/1 (599.9+/-141.0 ng . h/mL) (P=.030). The oral clearance of alprazolam was also significantly different between the CYP3A51/1 group (3.5+/-0.8 L/h) and CYP3A53/3 group (2.5+/-0.5 L/h) (P=.036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A53/3 (177.2+/-84.6) than in those with CYP3A51/*1 (107.5+/-44), the difference did not reach statistical significance (P=.148).

CONCLUSIONS

The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.